TRVI

Trevi Therapeutics Inc

Add to Watchlist

Advanced Chart

10.990

+0.34(3.192%)1D

Line

Candle

YTD

High

11.205

Open

10.590

VWAP

10.98

Vol

1.27M

Mkt Cap

1.41B

Low

10.460

Amount

13.94M

EV/EBITDA(TTM)

Total Shares

70.44M

1.21B

EV/OCF(TTM)

P/S(TTM)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.098

-11.36%

-0.125

+38.89%

-0.130

+44.44%

Estimates Revision

The market is revising No Change the revenue expectations for Trevi Therapeutics, Inc. (TRVI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 45.56%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+45.56%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 21.00 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.990

Low

16.00

Averages

21.00

High

25.00

Current: 10.990

Low

16.00

Averages

21.00

High

25.00

Oppenheimer

Leland Gershell

Outperform

maintain

$23 -> $24

2025-11-14

Reason

Oppenheimer

Leland Gershell

Price Target

$23 -> $24

2025-11-14

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on Trevi Therapeutics to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company provided updates across Haduvio's development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program - as well as advance into Phase 2b for refractory chronic cough - in the first half of 2026. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and Oppenheimer sees meaningful upside as Haduvio's momentum toward commercial builds for a growing group of poorly served chronic cough indications.

Morgan Stanley

Judah Frommer

Overweight

maintain

$18 -> $19

2025-11-14

Reason

Morgan Stanley

Judah Frommer

Price Target

$18 -> $19

2025-11-14

maintain

Overweight

Reason

Morgan Stanley analyst Judah Frommer raised the firm's price target on Trevi Therapeutics to $19 from $18 and keeps an Overweight rating on the shares after the company provided its third quarter update, noting incremental progress on the safety side if its Haduvio program and successful presentations at recent scientific meetings.

Clear Street

Buy

maintain

$11 -> $21

2025-11-14

Reason

Clear Street

Price Target

$11 -> $21

2025-11-14

maintain

Buy

Reason

Clear Street raised the firm's price target on Trevi Therapeutics to $21 from $11 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report. Trevi has completed the requirements for an end of Phase 2 meeting with the FDA and plans to request the meeting in Q4 to finalize its Phase 3 program in idiopathic pulmonary fibrosis-related chronic cough, the analyst tells investors in a research note. Clear cites regulatory path clarity for the target increase.

Morgan Stanley

Judah Frommer

Overweight

initiated

$18

2025-08-21

Reason

Morgan Stanley

Judah Frommer

Price Target

$18

2025-08-21

initiated

Overweight

Reason

Morgan Stanley analyst Judah Frommer initiated coverage of Trevi Therapeutics with an Overweight rating and $18 price target. The company is developing Haduvio, an extended-release formulation of nalbuphine for chronic cough, where existing therapies provide limited relief, the analyst tells investors in a research note. The firm sees a multi-billion dollar opportunity for Haduvio. The drug is "de-risked and differentiated" and should address a significant treatment gap, contends Morgan Stanley.

Raymond James

Strong Buy

downgrade

$29 -> $27

2025-08-08

Reason

Raymond James

Price Target

$29 -> $27

2025-08-08

downgrade

Strong Buy

Reason

Raymond James lowered the firm's price target on Trevi Therapeutics to $27 from $29 and keeps a Strong Buy rating on the shares. The firm believes Haduvio is the most efficacious treatment in clinical development for both IPF-chronic cough and refractory chronic cough, the analyst tells investors in a research note.

Cantor Fitzgerald

NULL -> Overweight

initiated

$25

2025-07-01

Reason

Cantor Fitzgerald

Price Target

$25

2025-07-01

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of Trevi Therapeutics with an Overweight rating and $25 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Trevi Therapeutics Inc (TRVI.O) is -21.49, compared to its 5-year average forward P/E of -6.18. For a more detailed relative valuation and DCF analysis to assess Trevi Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.18

Current PE

-21.49

Overvalued PE

-1.38

Undervalued PE

-10.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.63

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.21

Undervalued EV/EBITDA

-6.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00